References
- Headache Classification Committee. New appendix criteria open for a broader concept of chronic migraine. Cephalalgia26, 742–746 (2006).
- Robins E, Guze SB. Establishment of diagnostic validity in psychiatric illness: its application to schizophrenia. Am. J. Psychiatry126, 983–987 (1970).
- Haut SR, Bigal ME, Lipton RB. Chronic disorders with episodic manifestations: focus on epilepsy and migraine. Lancet Neurol.5, 148–157 (2006).
- Boardman HF, Thomas E, Millson DS, Croft PR. The natural history of headache: predictors of onset and recovery. Cephalalgia26, 1080–1088 (2006).
- Bille B. A 40-year follow-up of school children with migraine. Cephalalgia17, 488–491 (1997).
- Bigal ME, Lipton RB. When migraine progresses: transformed or chronic migraine. Expert Rev. Neurother.6, 297–306 (2006).
- D’Amico D, Grazzi L, Usai S, Rigamonti A, Curone M, Bussone G. Disability pattern in chronic migraine with medication overuse: a comparison with migraine without aura. Headache45, 553–560 (2005).
- Bigal ME, Rapoport AM, Lipton RB, Tepper SJ, Sheftell FD. Assessment of migraine disability using the migraine disability assessment (MIDAS) questionnaire: a comparison of chronic migraine with episodic migraine. Headache43, 336–342 (2003).
- Scher AI, Stewart WF, Ricci JA, Lipton RB. Factors associated with the onset and remission of chronic daily headache in a population-based study. Pain106, 81–89 (2003).
- Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache45(Suppl. 1), S3–S13 (2005).
- Bigal ME, Lipton RB. Modifiable risk factors for migraine progression. Headache46, 1334–1343 (2006).
- Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache41, 646–657 (2001).
- Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF; AMPP Advisory Group. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology68, 343–349 (2007).
- Bigal ME, Lipton RB. Obesity is a risk factor for transformed migraine but not chronic tension-type headache. Neurology67, 252–257 (2006).
- Bigal ME, Tsang A, Loder E, Serrano D, Reed ML, Lipton RB. Body mass index and episodic headaches: a population-based study. Arch. Intern. Med.167, 1964–1970 (2007).
- Winter AC, Berger K, Buring JE, Kurth T. Body mass index, migraine, migraine frequency and migraine features in women. Cephalalgia29, 269–278 (2009).
- Rueda-Sánchez M, Díaz-Martínez LA. Prevalence and associated factors for episodic and chronic daily headache in the Colombian population. Cephalalgia28, 216–225 (2008).
- Tietjen GE, Herial NA, Hardgrove J, Utley C, White L. Migraine comorbidity constellations. Headache47, 857–865 (2007).
- Tietjen GE, Peterlin BL, Brandes JL et al. Depression and anxiety: effect on the migraine–obesity relationship. Headache47, 866–875 (2007).
- Pompili M, Di Cosimo D, Innamorati M, Lester D, Tatarelli R, Martelletti P. Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. J. Headache Pain10, 283–290 (2009).
- Lipton RB, Bigal ME, Ashina S et al.; American Migraine Prevalence Prevention Advisory group. Cutaneous allodynia in the migraine population. Ann. Neurol.63, 148–158 (2008).
- Cooke L, Eliasziw M, Becker WJ. Cutaneous allodynia in transformed migraine patients. Headache47, 531–539 (2007).
- Lovati C, D’Amico D, Rosa S et al. Allodynia in different forms of migraine. Neurol. Sci.28(Suppl. 2), S220–S221 (2007).
- Ashkenazi A, Sholtzow M, Shaw JW, Burstein R, Young WB. Identifying cutaneous allodynia in chronic migraine using a practical clinical method. Cephalalgia27, 111–117 (2007).
- Burstein R, Cutrer MF, Yarnitsky D. The development of cutaneous allodynia during a migraine attack clinical evidence for the sequential recruitment of spinal and supraspinal nociceptive neurons in migraine. Brain123, 1703–1709 (2000).
- Sessle BJ, Hu JW, Amano N, Zhong G. Convergence of cutaneous, tooth pulp, visceral, neck and muscle afferents onto nociceptive and non-nociceptive neurones in trigeminal subnucleus caudalis (medullary dorsal horn) and its implications for referred pain. Pain27, 219–235 (1986).
- Mainero C, Zhang WT, Kumar A, Rosen BR, Sorensen AG. Mapping the spinal and supraspinal pathways of dynamic mechanical allodynia in the human trigeminal system using cardiac-gated fMRI. Neuroimage35(3), 1201–1210 (2007).
- Landy S, Rice K, Lobo B. Central sensitisation and cutaneous allodynia in migraine: implications for treatment. CNS Drugs18, 337–342 (2004).
- Welch KM, Nagesh V, Aurora SK, Gelman N. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache41, 629–637 (2001).
- Ferrari MD, Goadsby PJ, Roon KI, Lipton RB. Triptans (serotonin, 5-HT1B/1D agonists) in migraine: detailed results and methods of a meta-analysis of 53 trials. Cephalalgia22, 633–658 (2002).
- Bigal ME, Borucho S, Serrano D, Lipton RB. The acute treatment of episodic and chronic migraine in the USA. Cephalalgia29, 891–897 (2009).
- Silberstein SD, Neto W, Schmitt J, Jacobs D; MIGR-001 Study Group. Topiramate in migraine prevention: results of a large controlled trial. Arch. Neurol.61, 490–495 (2004).
- Silberstein SD, Lipton, RB, Dodick DW et al.Topiramate Chronic Migraine Study Group. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache47, 170–180 (2007).
- Yurekli VA, Akhan G, Kutluhan S, Uzar E, Koyuncuoglu HR, Gultekin F. The effect of sodium valproate on chronic daily headache and its subgroups. J. Headache Pain9, 37–41 (2008).
- Shuhendler AJ, Lee S, Siu M et al. Efficacy of botulinum toxin type A for the prophylaxis of episodic migraine headaches: a meta-analysis of randomized, double-blind, placebo-controlled trials. Pharmacotherapy29, 784–791 (2009).
- Freitag FG, Diamond S, Diamond M, Urban G. Botulinum toxin type A in the treatment of chronic migraine without medication overuse. Headache48, 201–209 (2008).
- Russell MB, Iselius L, Olesen J. Inheritance of migraine investigated by complex segregation analysis. Hum. Genet.96, 726–730 (1995).
- Stewart WF, Bigal ME, Kolodner K, Dowson A, Liberman JN, Lipton RB. Familial risk of migraine: variation by proband age at onset and headache severity. Neurology66, 344–348 (2006).
- Stewart WF, Staffa J, Lipton RB, Ottman R. Familial risk of migraine: a population-based study. Ann. Neurol.41, 166–172 (1997).
- Kruit MC, van Buchem MA, Hofman PA et al. Migraine as a risk factor for subclinical brain lesions. JAMA291, 427–434 (2004).
- Del Sette M, Dinia L, Bonzano L et al. White matter lesions in migraine and right-to-left shunt: a conventional and diffusion MRI study. Cephalalgia28, 376–382 (2008).
- Schmitz N, Admiraal-Behloul F, Arkink EB et al. Attack frequency and disease duration as indicators for brain damage in migraine. Headache48, 1044–1055 (2008).
- Kim JH, Suh SI, Seol HY et al. Regional grey matter changes in patients with migraine: a voxel-based morphometry study. Cephalalgia28, 598–604 (2008).
- Schmidt-Wilcke T, Gänssbauer S, Neuner T, Bogdahn U, May A. Subtle grey matter changes between migraine patients and healthy controls. Cephalalgia28, 1–4 (2008).
- Aurora SK, Barrodale P, Chronicle EP, Mulleners WM. Cortical inhibition is reduced in chronic and episodic migraine and demonstrates a spectrum of illness. Headache45, 546–552 (2005).
- Aurora SK, Barrodale PM, Tipton RL, Khodavirdi A. Brainstem dysfunction in chronic migraine as evidenced by neurophysiological and positron emission tomography studies. Headache47, 996–1003 (2007).